A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe (ACQUIRE)
A Prospective, Non-interventional Study Measuring Quality of Life, Treatment Preference and Treatment Satisfaction of Autosomal Dominant Polycystic Kidney Disease Patients in Europe
Sponsor: Otsuka Pharmaceutical Europe Ltd
This observational or N/A phase trial investigates Autosomal Dominant Polycystic Kidney Disease and is currently ongoing. Otsuka Pharmaceutical Europe Ltd leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Oct 2020 — Jan 2021 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
▶ Show 8 earlier versions
-
May 2019 — Oct 2020 [monthly]
Active Not Recruiting
-
Oct 2018 — May 2019 [monthly]
Active Not Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Recruiting NA
-
May 2017 — Oct 2017 [monthly]
Recruiting NA
-
Feb 2017 — May 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Europe Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Berlin, Germany , Brussels, Belgium , Edinburgh, United Kingdom , Geneva, Switzerland , Getafe, Spain , Glasgow, United Kingdom , Göttingen, Germany , Leuven, Belgium , Lille, France and 11 more locations